BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bulut AS, Erden E, Sak SD, Doruk H, Kursun N, Dincol D. Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases. Virchows Arch 2005;447:24-30. [PMID: 15947943 DOI: 10.1007/s00428-005-1250-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Fan C, Zhou J, Hu C. Expression of human papillomavirus in mammary carcinoma and its possible mechanism in carcinogenesis. Virol Sin 2008;23:226-31. [DOI: 10.1007/s12250-008-2914-2] [Reference Citation Analysis]
2 Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res 2015;17:25. [PMID: 25849745 DOI: 10.1186/s13058-015-0527-x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 16.0] [Reference Citation Analysis]
3 Chang CF, Diers AR, Hogg N. Cancer cell metabolism and the modulating effects of nitric oxide. Free Radic Biol Med 2015;79:324-36. [PMID: 25464273 DOI: 10.1016/j.freeradbiomed.2014.11.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.9] [Reference Citation Analysis]
4 Saied EM, El-Etreby NM. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours. Ann Diagn Pathol 2017;27:62-8. [PMID: 28325363 DOI: 10.1016/j.anndiagpath.2017.01.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
5 Hulin JA, Tommasi S, Elliot D, Hu DG, Lewis BC, Mangoni AA. MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1. Sci Rep 2017;7:13996. [PMID: 29070803 DOI: 10.1038/s41598-017-14454-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
6 Basudhar D, Somasundaram V, de Oliveira GA, Kesarwala A, Heinecke JL, Cheng RY, Glynn SA, Ambs S, Wink DA, Ridnour LA. Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression. Antioxid Redox Signal. 2017;26:1044-1058. [PMID: 27464521 DOI: 10.1089/ars.2016.6813] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
7 Korbecki J, Simińska D, Gąssowska-Dobrowolska M, Listos J, Gutowska I, Chlubek D, Baranowska-Bosiacka I. Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Molecular Mechanisms. Int J Mol Sci 2021;22:10701. [PMID: 34639040 DOI: 10.3390/ijms221910701] [Reference Citation Analysis]
8 Flaherty RL, Owen M, Fagan-Murphy A, Intabli H, Healy D, Patel A, Allen MC, Patel BA, Flint MS. Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer. Breast Cancer Res 2017;19:35. [PMID: 28340615 DOI: 10.1186/s13058-017-0823-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
9 El Hasasna H, Saleh A, Al Samri H, Athamneh K, Attoub S, Arafat K, Benhalilou N, Alyan S, Viallet J, Al Dhaheri Y, Eid A, Iratni R. Rhus coriaria suppresses angiogenesis, metastasis and tumor growth of breast cancer through inhibition of STAT3, NFκB and nitric oxide pathways. Sci Rep 2016;6:21144. [PMID: 26888313 DOI: 10.1038/srep21144] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
10 Mintz J, Vedenko A, Rosete O, Shah K, Goldstein G, Hare JM, Ramasamy R, Arora H. Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. Vaccines (Basel) 2021;9:94. [PMID: 33513777 DOI: 10.3390/vaccines9020094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
11 Cheng R, Glynn S, Flores-santana W, Switzer C, Ridnour L, Wink DA. Nitric Oxide and Redox Inflammation in Cancer. Elsevier; 2010. pp. 157-82. [DOI: 10.1016/s1872-0854(10)04005-1] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
12 Vesper BJ, Onul A, Haines GK 3rd, Tarjan G, Xue J, Elseth KM, Aydogan B, Altman MB, Roeske JC, Paradise WA, De Vitto H, Radosevich JA. Part I. Molecular and cellular characterization of high nitric oxide-adapted human breast adenocarcinoma cell lines. Tumour Biol 2013;34:203-14. [PMID: 23238815 DOI: 10.1007/s13277-012-0530-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
13 Arnold RS, Sun Q, Sun CQ, Richards JC, O'Hearn S, Osunkoya AO, Wallace DC, Petros JA. An inherited heteroplasmic mutation in mitochondrial gene COI in a patient with prostate cancer alters reactive oxygen, reactive nitrogen and proliferation. Biomed Res Int 2013;2013:239257. [PMID: 23509693 DOI: 10.1155/2013/239257] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
14 Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, Young HA, Trinchieri G, Wink DA. Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity. Clin Cancer Res 2013;19:1340-6. [PMID: 23271799 DOI: 10.1158/1078-0432.CCR-12-0408] [Cited by in Crossref: 93] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
15 Cheng R, Ridnour LA, Glynn SA, Switzer CH, Flores-santana W, Hussain P, Thomas DD, Ambs S, Harris CC, Wink DA. Nitric Oxide and Cancer: An Overview. In: Bonavida B, editor. Nitric Oxide (NO) and Cancer. New York: Springer; 2010. pp. 3-20. [DOI: 10.1007/978-1-4419-1432-3_1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Burke AJ, Garrido P, Johnson C, Sullivan FJ, Glynn SA. Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis. Antioxidants & Redox Signaling 2017;26:1078-90. [DOI: 10.1089/ars.2017.7004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
17 Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, Ambs S. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 2010;120:3843-54. [PMID: 20978357 DOI: 10.1172/JCI42059] [Cited by in Crossref: 142] [Cited by in F6Publishing: 97] [Article Influence: 11.8] [Reference Citation Analysis]
18 Nakhjavani M, Hardingham JE, Palethorpe HM, Price TJ, Townsend AR. Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. J Breast Cancer 2019;22:341-61. [PMID: 31598336 DOI: 10.4048/jbc.2019.22.e39] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
19 Keir ST, Dewhirst MW, Kirkpatrick JP, Bigner DD, Batinic-Haberle I. Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors. Anticancer Agents Med Chem 2011;11:202-12. [PMID: 21291403 DOI: 10.2174/187152011795255957] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
20 Sun X, Robertson SA, Ingman WV. Regulation of epithelial cell turnover and macrophage phenotype by epithelial cell-derived transforming growth factor beta1 in the mammary gland. Cytokine 2013;61:377-88. [PMID: 23290315 DOI: 10.1016/j.cyto.2012.12.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
21 Rahat MA, Hemmerlein B. Macrophage-tumor cell interactions regulate the function of nitric oxide. Front Physiol. 2013;4:144. [PMID: 23785333 DOI: 10.3389/fphys.2013.00144] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
22 Islam MS, Matsumoto M, Hidaka R, Miyoshi N, Yasuda N. Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis. Vet J 2012;192:338-44. [PMID: 22154426 DOI: 10.1016/j.tvjl.2011.08.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hirst D, Robson T. Targeting nitric oxide for cancer therapy. Journal of Pharmacy and Pharmacology 2007;59:3-13. [DOI: 10.1211/jpp.59.1.0002] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 7.0] [Reference Citation Analysis]
24 Ambs S, Glynn SA. Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. Cell Cycle 2011;10:619-24. [PMID: 21293193 DOI: 10.4161/cc.10.4.14864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
25 Carvalho SM, Soares FA, Netto MM, Nonogaki S, Castro RA. Is the expression of inducible (iNOS) and endothelial (eNOS) nitric oxide synthases an early event in breast carcinogenesis? Breast J 2010;16:440-1. [PMID: 20545936 DOI: 10.1111/j.1524-4741.2010.00945.x] [Reference Citation Analysis]
26 Pervin S, Chaudhuri G, Singh R. NO to breast: when, why and why not? Curr Pharm Des 2010;16:451-62. [PMID: 20236074 DOI: 10.2174/138161210790232130] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
27 Ozel E, Peştereli HE, Simşek T, Erdoğan G, Karaveli FS. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters? Int J Gynecol Cancer 2006;16:549-55. [PMID: 16681724 DOI: 10.1111/j.1525-1438.2006.00567.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
28 Nicolau CA, Prorock A, Bao Y, Neves-Ferreira AGDC, Valente RH, Fox JW. Revisiting the Therapeutic Potential of Bothrops jararaca Venom: Screening for Novel Activities Using Connectivity Mapping. Toxins (Basel) 2018;10:E69. [PMID: 29415440 DOI: 10.3390/toxins10020069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Hulin JA, Gubareva EA, Jarzebska N, Rodionov RN, Mangoni AA, Tommasi S. Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer. Front Oncol 2019;9:1455. [PMID: 31993367 DOI: 10.3389/fonc.2019.01455] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
30 Youness RA, Assal RA, Abdel Motaal A, Gad MZ. A novel role of sONE/NOS3/NO signaling cascade in mediating hydrogen sulphide bilateral effects on triple negative breast cancer progression. Nitric Oxide 2018;80:12-23. [PMID: 30081213 DOI: 10.1016/j.niox.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
31 Walsh EM, Keane MM, Wink DA, Callagy G, Glynn SA. Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes. Crit Rev Oncog 2016;21:333-51. [PMID: 29431082 DOI: 10.1615/CritRevOncog.2017021307] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
32 Parajuli N, Müller-holzner E, Böck G, Werner ER, Villunger A, Doppler W. Infiltrating CD11b + CD11c + cells have the potential to mediate inducible nitric oxide synthase-dependent cell death in mammary carcinomas of HER-2/neu transgenic mice: Infiltrating myeloid cells induce iNOS-dependent tumor cell death. Int J Cancer 2010;126:896-908. [DOI: 10.1002/ijc.24805] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
33 Vesper BJ, Elseth KM, Tarjan G, Haines GK 3rd, Radosevich JA. Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide. Tumour Biol 2010;31:267-75. [PMID: 20480412 DOI: 10.1007/s13277-010-0028-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
34 Özenver N, Efferth T. Small molecule inhibitors and stimulators of inducible nitric oxide synthase in cancer cells from natural origin (phytochemicals, marine compounds, antibiotics). Biochem Pharmacol 2020;176:113792. [PMID: 31926145 DOI: 10.1016/j.bcp.2020.113792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Monteiro HP, Rodrigues EG, Amorim Reis AK, Longo LS, Ogata FT, Moretti AI, da Costa PE, Teodoro AC, Toledo MS, Stern A. Nitric oxide and interactions with reactive oxygen species in the development of melanoma, breast, and colon cancer: A redox signaling perspective. Nitric Oxide 2019;89:1-13. [DOI: 10.1016/j.niox.2019.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
36 Dabbeche-Bouricha E, Hadiji-Abbes N, Abdelmaksoud-Damak R, Alaya N, Ayadi W, Charfi S, Khabir A, Sellami-Boudawara T, Mokdad-Gargouri R. Quantitative measurement of iNOS expression in melanoma, nasopharyngeal, colorectal, and breast tumors of Tunisian patients: comparative study and clinical significance. Tumour Biol 2016;37:5153-64. [PMID: 26547585 DOI: 10.1007/s13277-015-4303-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
37 Pasha A, Kumbhakar DV, Doneti R, Kumar K, Dharmapuri G, Poleboyina PK, S K H, Basavaraju P, Pasumarthi D, S D A, Soujanya P, Arnold Emeson I, Bodiga V, Pawar SC. Inhibition of Inducible Nitric Oxide Synthase (iNOS) by Andrographolide and In Vitro Evaluation of Its Antiproliferative and Proapoptotic Effects on Cervical Cancer. Oxid Med Cell Longev 2021;2021:6692628. [PMID: 33815659 DOI: 10.1155/2021/6692628] [Reference Citation Analysis]
38 Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013;34:503-12. [PMID: 23354310 DOI: 10.1093/carcin/bgt034] [Cited by in Crossref: 222] [Cited by in F6Publishing: 202] [Article Influence: 24.7] [Reference Citation Analysis]
39 Oplawski M, Dziobek K, Zmarzły N, Grabarek BO, Kiełbasiński R, Kieszkowski P, Januszyk P, Talkowski K, Schweizer M, Kras P, Plewka A, Boroń D. Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer. Curr Pharm Biotechnol 2020;21:52-9. [PMID: 31533599 DOI: 10.2174/1389201020666190918104105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]